Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.

Stadler, W M; Kuzel, T; Roth, B; Raghavan, D; Dorr, F A

Stadler, W M; Kuzel, T; Roth, B; Raghavan, D; Dorr, F A.

Affiliation

Stadler WM; University of Chicago, and Northwestern University Medical School, Chicago, IL 60637, USA. wmstadle@mcis.bsd.uchicago.edu

J Clin Oncol ; 15(11): 3394-8, 1997 Nov.

Article in En | MEDLINE | ID: mdl-9363871

Subject(s)

Antimetabolites, Antineoplastic/therapeutic use; Carcinoma, Transitional Cell/drug therapy; Carcinoma, Transitional Cell/secondary; Deoxycytidine/analogs & derivatives; Urinary Bladder Neoplasms/drug therapy; Urinary Bladder Neoplasms/pathology; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic/adverse effects; Deoxycytidine/adverse effects; Deoxycytidine/therapeutic use; Female; Humans; Male; Middle Aged; Survival Analysis; Treatment Outcome; Gemcitabine

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell / Deoxycytidine / Antimetabolites, Antineoplastic Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: J Clin Oncol Year: 1997 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links